INVA logo

Innoviva Inc. (INVA)

$18.30

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on INVA

Market cap

$1.30B

EPS

2.24

P/E ratio

4.8

Price to sales

3.48

Dividend yield

--

Beta

0.376069

Price on INVA

Previous close

$18.49

Today's open

$18.39

Day's range

$18.28 - $18.58

52 week range

$18.28 - $25.15

Profile about INVA

CEO

Pavel Raifeld

Employees

159

Headquarters

Burlingame, CA

Exchange

Nasdaq Global Select

Shares outstanding

71081477

Issue type

Common Stock

INVA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on INVA

Replenish Your Portfolio With These 5 Low Price-to-Sales Stocks

Low P/S ratios, solid fundamentals and manageable debt can help uncover undervalued stocks with upside potential. Explore INVA, DINO, PARR, GPRE and PBF.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Is Innoviva (INVA) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

news source

Zacks Investment Research • Nov 10, 2026

news preview

INVA or MRK: Which Is the Better Value Stock Right Now?

Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value opportunity right now?

news source

Zacks Investment Research • Nov 9, 2026

news preview

Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements. “IST delivered anoth.

news source

Business Wire • Nov 4, 2026

news preview

Innoviva (INVA) Tops Q3 Earnings Estimates

Innoviva (INVA) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.08 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). The meeting will be held October 21–24, 2026, at the Walter E. Washington Conventio.

news source

Business Wire • Oct 19, 2026

news preview

Do Options Traders Know Something About Innoviva Stock We Don't?

Investors need to pay close attention to INVA stock based on the movements in the options market lately.

news source

Zacks Investment Research • Oct 12, 2026

news preview

Should Value Investors Buy Innoviva (INVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

news source

Zacks Investment Research • Oct 8, 2026

news preview

5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential

DINO, INVA, PARR, GNW and PBF stand out as low price-to-sales stocks with promising upside potential. Discover how attractive valuations can uncover hidden value.

news source

Zacks Investment Research • Oct 8, 2026

news preview

INVA vs. MRK: Which Stock Is the Better Value Option?

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Innoviva (INVA) or Merck (MRK). But which of these two stocks is more attractive to value investors?

news source

Zacks Investment Research • Oct 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Innoviva Inc.

Open an M1 investment account to buy and sell Innoviva Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in INVA on M1